2023
Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study
Fusar-Poli L, Prachason T, Erzin G, Pries L, Brondino N, Politi P, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Escarti M, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Üçok A, Alptekin K, Saka M, Arango C, O'Donovan M, van Os J, Rutten B, Guloksuz S, investigators G. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. Psychiatry Research 2023, 323: 115184. PMID: 37015164, DOI: 10.1016/j.psychres.2023.115184.Peer-Reviewed Original ResearchConceptsBenton Facial Recognition TestDegraded Facial Affect Recognition TaskWechsler Adult Intelligence Scale-Third EditionSchizophrenia spectrum disordersSocial cognitionCognitive domainsFacial affect recognition taskAffect recognition taskFacial Recognition TestCognitive impairmentRecognition testSpectrum disorderRecognition taskCross-sectional sampleHealthy controlsCognitionPsychosis spectrumShort versionUnaffected siblingsNeurocognitionEUGEI studySchizophreniaPerceptionImpairmentSiblingsExamining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Findings from the EUGEI study
Fusar-Poli L, Investigators E, Investigators G, van Os J, Rutten B, Guloksuz S. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Findings from the EUGEI study. European Psychiatry 2023, 66: s445-s445. PMCID: PMC10434418, DOI: 10.1192/j.eurpsy.2023.957.Peer-Reviewed Original ResearchWechsler Adult Intelligence ScaleSchizophrenia spectrum disordersSocial cognitionFacial emotion recognition taskUnaffected siblingsEmotion recognition taskAdult Intelligence ScaleDisclosure of interestCognitive domainsIntelligence ScaleSpectrum disorderRecognition taskCognitionHealthy controlsNeurocognitionLongitudinal studyPresent cross-sectional studyEUGEI studyMolecular genetic riskSchizophreniaAssociations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia
Lin B, Pinzón-Espinosa J, Blouzard E, van der Horst M, Okhuijsen-Pfeifer C, van Eijk K, Guloksuz S, Peyrot W, Luykx J, Hasan A, Wagner E, Pantelis C, Everall I, Ayhan Y, Babaoğlu M, Bak M, Alink W, Beld E, Bouhuis A, Edlinger M, Erdoğan I, Gutwinski S, Hallikainen T, Jeger-land E, Lähteenvuo M, de Koning M, Morgenroth C, Müderrisoğlu A, Oviedo-Salcedo T, Schreiter S, Repo-Tiihonen E, Tuppurainen H, Veereschild M, Veerman S, de Vos M, Cohen D, Bogers J, Anıl Yağcıoğlu A, Tiihonen J, Ripke S, Bousman C, Van Beek H, Okhuijsen-Pfeifer C, van der Horst M, van Eijk K, Ertuğrul A, Yoca G, Görlitz T, Grootens K, Leucht S, Narang A, Schneider-Thoma J, Kahn R, Bekema E, Kleymann P, Luykx J, Alizadeh B, van Amelsvoort T, Cahn W, de Haan L, Schirmbeck F, Simons C, van Os J, Rutten B, van Winkel R. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia. JAMA Psychiatry 2023, 80: 181-185. PMID: 36542388, PMCID: PMC9857760, DOI: 10.1001/jamapsychiatry.2022.4234.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersRisk ratioPolygenic risk scoresUnrelated healthy controlsRisk scorePRS-SCZClozapine useHealthy controlsOdds ratioCourse of illnessHigher likelihoodPsychosis liabilityClozapine prescribingClozapine prescriptionPharmacotherapy choicesClozapine treatmentObservational cohortMedication useAntipsychotic useAntipsychotic treatmentMAIN OUTCOMEMultinomial logistic regressionPrognostic studiesAntipsychoticsEarly intervention
2021
Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review
Sneller M, de Boer N, Everaars S, Schuurmans M, Guloksuz S, Cahn W, Luykx J. Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review. Frontiers In Psychiatry 2021, 12: 625935. PMID: 33868046, PMCID: PMC8044798, DOI: 10.3389/fpsyt.2021.625935.Peer-Reviewed Original ResearchSecond-generation antipsychoticsC-reactive proteinSchizophrenia spectrum disordersMetabolic syndromeCurrent BMIGenetic factorsHigher ageHigher white blood cell countSystematic reviewWhite blood cell countSevere mental illness experienceHigher baseline BMIRisk of MetS.Cardiovascular disease mortalityBlood cell countCross-sectional studyHigher current BMIMore studiesMental illness experienceSpectrum disorderSGA exposureBaseline BMICohort studyClinical factorsTobacco smokingAssociation of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings
Noyan H, Erdağ E, Tüzün E, Yaylım İ, Küçükhüseyin Ö, Hakan M, Gülöksüz S, Rutten B, Saka M, Atbaşoğlu C, Alptekin K, van Os J, Üçok A. Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings. Schizophrenia Research 2021, 229: 27-37. PMID: 33609988, DOI: 10.1016/j.schres.2021.01.014.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersIL-1β levelsKYNA levelsHigher serum IL-1β levelsSerum IL-1β levelsHigher KYNA levelsTrp-Kyn pathwayKynurenic acid levelsSimilar clinical featuresPathophysiology of schizophreniaManifestations of schizophreniaKYN levelsSerum interleukinClinical featuresInflammatory cytokinesIL-1βClinical dataKynurenine pathwayTRP levelsSpectrum disorderControl groupAdvanced stageLow TrpPathway dysregulationPatientsStudy protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial
de Boer N, Guloksuz S, van Baal C, Willebrands L, Deenik J, Vinkers C, Rossum I, Zinkstok J, Wilting I, Zantvoord J, Backx F, Swildens W, Schouw M, Bogers J, Hulshof F, de Knijff R, Duindam P, Veereschild M, Bak M, Frederix G, de Haan L, van Os J, Cahn W, Luykx J. Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial. BMC Psychiatry 2021, 21: 4. PMID: 33402159, PMCID: PMC7783702, DOI: 10.1186/s12888-020-02992-4.Peer-Reviewed Original ResearchConceptsNetherlands Trial RegisterLifestyle interventionQuality of lifeTreatment inceptionOutcome measuresWeight gainAntipsychotic-induced weight gainSafety of metforminUse of metforminCommon adverse effectsSecondary outcome measuresPrimary outcome measureWeeks of treatmentBody weight lossMulti-center trialType 2 diabetesMajor health problemYears of ageSchizophrenia spectrum disordersTrials RegisterMetabolic syndromeOptimal management strategyExercise programMetformin treatmentDietary consultation
2020
Predictive Performance of Exposome Score for Schizophrenia in the General Population
Pries L, Erzin G, van Os J, Have M, de Graaf R, van Dorsselaer S, Bak M, Rutten B, Guloksuz S. Predictive Performance of Exposome Score for Schizophrenia in the General Population. Schizophrenia Bulletin 2020, 47: 277-283. PMID: 33215211, PMCID: PMC7965069, DOI: 10.1093/schbul/sbaa170.Peer-Reviewed Original ResearchConceptsES-SCZOptimal cut pointGeneral populationPopulation cohortGeneral population cohortCut pointsExposome scoreSchizophrenia spectrum disordersMeta-analytical estimatesClinical outcomesRisk strataRisk stratificationMulticausal etiologyMedical outcomesPsychiatric diagnosisBipolar disorderSchizophrenia diagnosisExposure scoreSuicide planSum scoreGene-environment interaction studiesSchizophreniaRisk predictionCharacteristic curveScoresEvidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway
van Os J, Pries L, Have M, de Graaf R, van Dorsselaer S, Delespaul P, Bak M, Kenis G, Lin B, Luykx J, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Aguilar E, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Rutten B, Guloksuz S. Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. Psychological Medicine 2020, 52: 1910-1922. PMID: 33070791, DOI: 10.1017/s0033291720003748.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersChildhood adversityRisk factorsNEMESIS-2Affective dysregulationNon-genetic risk factorsSignificant depressive symptomsSample of patientsRepresentative general population sampleGenetic risk factorsGeneral population sampleSchizophrenia polygenic riskPsychosis outcomesSpectrum disorderDepressive symptomsPRS-SZPolygenic riskDysregulationPatientsPopulation samplePsychosisAffective pathwayDisordersHallucinatory experiencesDelusional ideationA replication study of JTC bias, genetic liability for psychosis and delusional ideation
Henquet C, van Os J, Pries L, Rauschenberg C, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Aguilar E, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Rutten B, Gülöksüz S. A replication study of JTC bias, genetic liability for psychosis and delusional ideation. Psychological Medicine 2020, 52: 1777-1783. PMID: 33046166, PMCID: PMC9280279, DOI: 10.1017/s0033291720003578.Peer-Reviewed Original Research
2019
Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study
Guloksuz S, Pries L, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş‐Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Cabrera B, Bobes J, Saiz P, García‐Portilla M, Sanjuan J, Aguilar E, Santos J, Jiménez‐López E, Arrojo M, Carracedo A, López G, González‐Peñas J, Parellada M, Maric N, Atbaşog˘lu C, Ucok A, Alptekin K, Saka M, investigators G, Arango C, O'Donovan M, Rutten B, van Os J. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry 2019, 18: 173-182. PMID: 31059627, PMCID: PMC6502485, DOI: 10.1002/wps.20629.Peer-Reviewed Original ResearchSchizophrenia spectrum disordersEnvironmental exposuresGene-environment interactionsEtiopathogenesis of schizophreniaAdditive interactionEarly life adversityEarly TwinSeason of birthPolygenic risk scoresSpectrum disorderMultiple common genetic variantsRisk scoreRegular cannabisLifetime historyJoint associationsPRS-SCZCommon genetic variantsHearing impairmentSchizophreniaUnrelated controlsEUGEI studyDisordersFamily studiesGenetic liabilityRisk state
2018
An Economic Evaluation of Coordinated Specialty Care (CSC) Services for First-Episode Psychosis in the U.S. Public Sector.
Murphy SM, Kucukgoncu S, Bao Y, Li F, Tek C, Breitborde NJK, Guloksuz S, Phutane VH, Ozkan B, Pollard JM, Cahill JD, Woods SW, Cole RA, Schoenbaum M, Srihari VH. An Economic Evaluation of Coordinated Specialty Care (CSC) Services for First-Episode Psychosis in the U.S. Public Sector. The Journal Of Mental Health Policy And Economics 2018, 21: 123-130. PMID: 30530872, PMCID: PMC6314808.Peer-Reviewed Original ResearchConceptsSpecialty care servicesPatient costsEarly intervention servicesUsual treatmentSchizophrenia spectrum disordersMonth 12Economic evaluationCare servicesSTEP participantsCommunity mental health centerThird-party payer perspectiveIntervention servicesFirst-episode servicesMonths post randomizationHealthcare service utilizationMental health centersU.S. public sectorTeam-based careCost-offset analysisEligible patientsThird-party payersAntipsychotic exposureED visitsMonth 6Episode psychosis